PMID- 24023298
OWN - NLM
STAT- MEDLINE
DCOM- 20131127
LR  - 20130911
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 33
IP  - 9
DP  - 2013 Sep
TI  - Tropomyosin-related kinase B inhibitor has potential for tumor regression and 
      relapse prevention in pulmonary large cell neuroendocrine carcinoma.
PG  - 3699-703
AB  - Large cell neuroendocrine carcinoma (LCNEC) has an especially poor prognosis, and 
      an effective therapeutic strategy has yet to be established. We have previously 
      shown that the expressions of tropomyosin-related kinase B (TRKB) and 
      brain-derived neurotrophic factor (BDNF) are high in LCNEC and that TRKB/BDNF 
      signaling is involved in the proliferation, tumorigenesis, and invasive nature of 
      LCNEC. Therefore, TRKB/BDNF signaling may offer a potential therapeutic target 
      for LCNEC treatment. In the present study, we evaluated whether the TRKB tyrosine 
      kinase inhibitor, k252a, has effects on tumor regression and relapse prevention 
      on LCNEC, using a murine xenograft model. The LCNEC cell line and NCI-H810 cells 
      were subcutaneously implanted into the flanks or intrathoracically injected into 
      the bilateral pleural cavities of BALB/c nude mice. k252a significantly inhibited 
      tumor volume, expression of matrix metalloproteinases and the formation of 
      pleural dissemination by LCNEC. These results suggest that k252a has potential 
      for tumor regression and relapse prevention in LCNEC. Since many patients with 
      LCNEC suffer through the use of ineffective therapeutic strategies, a clinical 
      trial using the TRKB inhibitor for LCNEC is urgently required.
FAU - Odate, Seiichi
AU  - Odate S
AD  - Department of Cancer Therapy and Research, Graduate School of Medical Sciences, 
      Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. 
      ohnishi@surg1.med.kyushu-u.ac.jp.
FAU - Onishi, Hideya
AU  - Onishi H
FAU - Nakamura, Katsuya
AU  - Nakamura K
FAU - Kojima, Masayuki
AU  - Kojima M
FAU - Uchiyama, Akihiko
AU  - Uchiyama A
FAU - Kato, Masato
AU  - Kato M
FAU - Katano, Mitsuo
AU  - Katano M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Carbazoles)
RN  - 0 (Indole Alkaloids)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 97161-97-2 (staurosporine aglycone)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.28 (tropomyosin kinase)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Carbazoles/*pharmacology
MH  - Carcinoma, Large Cell/enzymology/*pathology
MH  - Carcinoma, Neuroendocrine/enzymology/*pathology
MH  - Cell Line, Tumor
MH  - Female
MH  - Humans
MH  - Indole Alkaloids/*pharmacology
MH  - Lung Neoplasms/enzymology/*pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Protein Kinase Inhibitors/*pharmacology
MH  - Protein Kinases/*drug effects
MH  - Recurrence
OTO - NOTNLM
OT  - BDNF
OT  - Large cell neuroendocrine carcinoma
OT  - TRKB
OT  - invasion
OT  - lung cancer
OT  - tumorigenicity
EDAT- 2013/09/12 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/09/12 06:00
PHST- 2013/09/12 06:00 [entrez]
PHST- 2013/09/12 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - 33/9/3699 [pii]
PST - ppublish
SO  - Anticancer Res. 2013 Sep;33(9):3699-703.